Transforming drug development with AI
Posted: 29 November 2024 | Drug Target Review | No comments yet
Tune in to this episode to hear the latest insights about the role of AI and data in transforming the healthcare landscape.
In this episode, titled ‘Transforming drug development with AI‘, we will discuss the role of AI and data in transforming the healthcare landscape.
This conversation features Dr Milan Radovich, Senior Vice President and Chief Scientific Officer at Caris Life Sciences, and Yochi Slonim, co-founder, CEO and Board Member at Anima Biotech.
Key discussion points
- How companies are already implementing AI to benefit patients
- What the future of healthcare looks like with AI
- Is AI generating too much data? How can we sort through genetic links to discern which ones are more important than others?
This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.
About our speakers
Dr Milan Radovich, Senior Vice President and Chief Scientific Officer at Caris Life Sciences
Dr Milan Radovich joined Caris Life Sciences in September 2021 and currently serves as Senior Vice President and Chief Scientific Officer. In this role, he leads Caris’ efforts in data-driven scientific advancements in genomic medicine, liquid biopsy, translational research, clinical trials, target discovery and drug development. He also works closely with our numerous academic and biopharma collaborators on joint research in precision medicine.
Before joining Caris, Dr. Radovich was an associate professor at the Indiana University School of Medicine and Vice President for Oncology Genomics at Indiana University Health. At IU, he led a clinical program dedicated to the integration of cutting-edge genomics for the care of advanced cancer patients. His research expertise focused on the use of genomics in translational oncology with a focus on clinical trials, genomically-informed drug combinations, liquid biopsy & MRD, and creating novel bioinformatic pipelines for cancer genome analyses. His work has been published in many high-impact journals and presented at international oncology meetings.
Yochi Slonim, Msc, co-founder, CEO and Board Member at Anima Biotech
A serial entrepreneur in software and biotech, Yochi Slonim has built multiple companies as a founder and CEO through all phases of growth all the way to IPOs and large M&A exits. As a Co-founder and CEO of Anima Biotech, he is driving the company’s strategy and business development at the intersection of mRNA biology and AI.
Prior to Anima, Yochi was a co-founder of Mercury Interactive. As CTO and VP R&D from the company’s early days, he created product vision and strategy and led a multi-product organization of 200 developers. After going public and reaching revenues of over $1B annually, Mercury was acquired by HP for $4.5B.
As Senior VP of products and marketing for Tecnomatix, a public NASDAQ company, he led a 500 people organization of 4 divisions that generated revenues of $100m until the company was acquired by UGS for $230m.
In 2000, Yochi was founder and CEO of Identify. The company reached revenues of $50m in less than 5 years and was acquired by BMC in 2006 for $150m in cash.
Yochi founded ffwd.me, a unique startup acceleration program where he led a team that worked with over 25 startups in diverse areas and technologies, developing strategy, products and go to market operations while raising multiple rounds of financing from VCs and private investors.
As one of Israel’s leading speakers on the subject of startup positioning and company building, several of Yochi’s approachable and amusing lectures can be found on Youtube (“Youtube Yochi Slonim”).
Related topics
Artificial Intelligence, Oncology
Related organisations
Anima Biotech, Caris Life Sciences